

**ASX Release**

28 April 2026

**APPOINTMENT OF DIRECTORS**

**MELBOURNE, AUSTRALIA 28 April 2026:** Arovella Therapeutics Ltd (ASX: ALA) (**Arovella** or the **Company**), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, advises that it has today appointed new Directors to the Board.

As shareholders are aware, the Board has been undertaking a skills evaluation as part of its broader succession strategy, to identify suitable candidates to complement the expertise currently represented on the Board. The Board is pleased to advise that, following an extensive process, seasoned Pharma/Biotech executive **Dr. Mike Perry** has agreed to join the Board as Non-Executive Director, effective 28 April 2026.

Dr. Perry has deep experience in board and leadership roles, having served as VP & EVP of Regulatory Affairs, Chief Executive Officer (CEO), President, Chief Scientific Officer (CSO), Chief Development Officer (CDO), and Venture Partner across leading organisations including Novartis Pharma, Baxter Healthcare, Syntex Corporation (acquired by Roche), Schering Plough (acquired by Merck), Bay City Capital, LLC, Avita Medical and others.

The Board also advises of the additional appointments of Messrs **David Williams**, **Mark Diamond** and **Michael Thurn** as Non-Executive Directors, effective 28 April 2026. Messrs Williams, Diamond and Thurn were candidates nominated to the Board by 5.55% shareholder The Trust Company (Australia) Limited ACN 000 000 993 as custodian for CIP Licensing Limited ACN 603 558 658 as responsible entity of the Summit Biotech Fund ARSN 664 495 468, in a (now withdrawn) section 249D notice.

**About Dr. Mike Perry***Qualifications*

Dr. Perry holds an Honours BS (Physics and Engineering) and a PhD (Biomedical Pharmacology) from the University of Guelph, Ontario, Canada. He has also earned a DVM (Doctor of Veterinary Medicine & Surgery) from Ontario Veterinary College and he is a graduate of the International Advanced Management Program at Harvard Business School.

*Experience*

Dr. Perry has over 30 years' global experience in Biotech, Pharma, Medtech, Cell & Gene Therapy, siRNA, and Venture Capital. Dr. Perry's leadership and management skills span the entire product lifecycle from late discovery through all phases of development, to regulatory approval, and initial commercial launch. He has deep board governance experience with over 25 years of board service on both public and private boards, including NYSE-, NASDAQ-, ASX-, and TASE-listed companies. He has served on and chaired key committees including Audit, Compensation, and Nomination/Governance. He has also served as Lead Independent Director. His board leadership is backed by rigorous training through VC funded companies, training at Harvard Business School, and hands-on IPO and M&A execution.

**ASX: ALA**

Arovella Therapeutics Limited  
ACN 090 987 250



Dr. Perry is passionate about translating medical innovations into meaningful high impact therapies for patients, building high-performing executive teams, and maximising stakeholder value.

*Current public company directorships*

Dr. Perry is a director of Arrowhead Pharmaceuticals (NASDAQ: ARWR).

**About Mr David Williams**

*Qualifications*

Mr Williams holds a B.Com (Hons) & Master of Economics from La Trobe University, a PhD Research in Finance from the University of Sydney and is a fellow of the AICD.

*Experience*

Mr Williams is an experienced director and corporate advisor with over 4 decades experience in advising ASX listed companies with expertise in business development, M&A and capital markets.

*Current public company directorships*

Mr Williams is currently a director of RMA Global Limited (ASX:RMY) and Kidder Williams Limited.

**About Mr Mark Diamond**

*Qualifications*

Mr Diamond holds a BSc from Monash University, and MBA from Macquarie University.

*Experience*

Mr Diamond is an experienced senior executive, who previously served as CEO of Antisense Therapeutics Limited (now Percheron Therapeutics ASX:PER).

Mr Diamond has a successful track record in funding, licencing deals, and partnerships. He is currently Biotech Advisor to Spark Plus and Locust Walk, and his global C-Suite executive leadership experience spans healthcare strategy, compliance and risk management, financial management, and board governance.

*Current public company directorships*

Mr Diamond is currently non-executive chair of Dimerix Ltd (ASX:DXB).

**About Mr Michael Thurn**

*Qualifications*

Mr Thurn holds a BAppSc (Hons) from UTS, and Doctor of Philosophy (Ph.D) from UTS.

*Experience*

Mr Thurn is an experienced biotechnology executive and company director with more than 25 years' experience across drug discovery, preclinical and clinical development, regulation, commercialisation,

**ASX: ALA**

Arovella Therapeutics Limited  
ACN 090 987 250



capital raising and corporate leadership. He has held senior executive roles in both private and ASX-listed life sciences companies, including as Managing Director and Chief Executive Officer of Neurizon Therapeutics Limited (ASX: NUZ) (formerly PharmAust Limited), co-founder and Executive Director of MARP Therapeutics, Chief Operating Officer and Executive Director of Botanix Pharmaceuticals, and Chief Executive Officer of Mimetica and Spinifex Pharmaceuticals. He has also served in regulatory review at the Therapeutic Goods Administration.

*Current public company directorships*

Mr Thurn is currently a director of Neurizon Therapeutics Limited (ASX: NUZ), until July 2026.

Arovella's CEO and MD, Dr Michael Baker, commented: "We welcome the appointment of the new board members and the experience they bring, as the Company continues its work to develop its CAR-iNKT cell platform for cancer treatment. We look forward to working towards the creation of long-term value for shareholders."

This announcement has been authorised for release by the Company's Board of Directors.

**Dr Michael Baker**

**Chief Executive Officer & Managing Director**

**Arovella Therapeutics Ltd**

Tel +61 (0) 403 468 187

investor@arovella.com

**NOTES TO EDITORS:****About Arovella Therapeutics Ltd**

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 has had its Investigational New Drug application (IND) accepted by the US FDA and is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

**Glossary:** **iNKT cell** – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **aGalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit [www.arovella.com](http://www.arovella.com)

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding the actions of third parties and financial terms. These factors and assumptions are based upon currently available information, and the forward-looking statements herein speak only of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; the risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.